VRTX · 8-K · 20261102PR000287

ALYFTREK Market Access

VERTEX PHARMACEUTICALS INC / MA · 2026-11-02 · Importance 26 · Surprise 24

Vertex secured reimbursement for ALYFTREK in seven additional countries in the third quarter of 2026, bringing the total to 32 countries. The company also initiated global regulatory submissions for ALYFTREK for children with cystic fibrosis ages 2 to 5 years. These disclosures indicate expanding access and a planned age-group expansion for the CF therapy.

Key facts

• Vertex secured ALYFTREK reimbursement in seven additional countries in third-quarter 2026, bringing the total to 32 countries. source
• Vertex initiated global regulatory submissions for ALYFTREK for children with CF ages 2 to 5 years. source